Zobrazeno 1 - 10
of 99
pro vyhledávání: '"Mark A Wainberg"'
Autor:
Vladimir Novitsky, Simani Gaseitsiwe, Max Essex, Joseph Makhema, Richard Marlink, Harriet Okatch, Sikhulile Moyo, Thabo Diphoko, Ishmael Kasvosve, Mark A. Wainberg, Rosemary Musonda
Publikováno v:
AIDS Research and Human Retroviruses. 34:667-671
Rilpivirine (RPV) and Etravirine (ETR) are approved second-generation non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV treatment. There is a cross-resistance HIV mutation profile between first- and second-generation NNRTI drugs. We de
Publikováno v:
Pathogens and Immunity, Vol 1, Iss 1, Pp 41-67 (2016)
Pathogens & Immunity
Pathogens & Immunity
Since the discovery of the first inhibitors of HIV replication, drug resistance has been a major problem in HIV therapy, due, in part, to the high mutation rate of HIV. Therefore, the development of a predictive animal model is important to identify
Autor:
Jing Leng, Mark A. Wainberg, Hanh T. Pham, Yudong Quan, Thibault Mesplède, Jiaming Liang, Ying-Shan Han
Publikováno v:
mBio, Vol 9, Iss 5 (2018)
mBio, Vol 9, Iss 5, p e01450-18 (2018)
mBio, Vol 9, Iss 5, p e01450-18 (2018)
Volume 8, no. 2, e00157-17, 2017, [https://doi.org/10.1128/mBio.00157-17][1]. One source of funding for our study was not properly acknowledged. The acknowledgment section of the manuscript should read: We regret to note that Mark A. Wainberg passed
Autor:
Keith W Crawford, Catherine Godfrey, Daniel R. Kuritzkes, Michael C Thigpen, Patrick Jean-Phillippe, Elliot Raizes, Deborah Persaud, Deenan Pillay, Joseph E. Fitzgibbon, Mark A. Wainberg
Publikováno v:
The Journal of Infectious Diseases. 216:S798-S800
Autor:
Mark A. Wainberg
Publikováno v:
Future Virology. 11:607-609
Dr Mark A Wainberg is Professor of Medicine and Microbiology and Immunology at McGill University (Montreal, Canada) and Director of the McGill University AIDS Centre. He served as President of the International AIDS Society between 1998 and 2000 with
Autor:
Mark A. Wainberg, Thibault Mesplède
Publikováno v:
Viruses
Viruses, Vol 7, Iss 7, Pp 3703-3718 (2015)
Viruses, Vol 7, Iss 7, Pp 3703-3718 (2015)
Drug resistance prevents the successful treatment of HIV-positive individuals by decreasing viral sensitivity to a drug or a class of drugs. In addition to transmitted resistant viruses, treatment-naïve individuals can be confronted with the problem
Autor:
Thomas Szekeres, Yudong Quan, Hongtao Xu, Mark A. Wainberg, Thibault Mesplède, Peter K. Quashie, Ying-Shan Han, Walter Jaeger
Publikováno v:
Journal of Medical Virology. 87:2054-2060
HIV resistance to current anti-HIV drugs and drug toxicity have created a need for new anti-HIV agents. We have examined and characterized a synthetic resveratrol analog, termed 3,3′,4,4′,5,5′-hexahydroxy-trans-stilbene (M8), for potential anti
Autor:
Maureen Oliveira, Thibault Mesplède, Mark A. Wainberg, Bluma G. Brenner, Daniela Moisi, Ilinca Ibanescu, Frédéric Ohnona
Publikováno v:
AIDS. 29:659-665
OBJECTIVE In treatment-naive HIV-positive individuals, the integrase strand-transfer inhibitor dolutegravir (DTG) has not been associated with emergent drug-resistance mutations, neither against this drug nor against other antiretroviral drugs that w
Autor:
Victor G. Kramer, Wei-Lie Xiao, Hongtao Xu, Yudong Quan, Maureen Oliveira, Thibault Mesplède, Ying-Shan Han, Susan P. Colby-Germinario, Han-Dong Sun, Mark A. Wainberg
Publikováno v:
Antiviral Chemistry and Chemotherapy. 24:28-38
Background Due to resistance to all classes of anti-HIV drugs and drug toxicity, there is a need for the discovery and development of new anti-HIV drugs. Methods HIV-1 inhibitors were identified and biologically characterized for mechanism of action.
Autor:
Victor G. Kramer, Mark A. Wainberg
Publikováno v:
Future Virology. 10:97-112
HIV resistance against currently approved entry inhibitors, the chemokine receptor-5 (CCR5) antagonist maraviroc and the fusion inhibitor enfuvirtide (T-20), manifests in a complex manner that is distinct from the resistance patterns against other cl